The purpose of this study is to evaluate 1 year extension study of the efficacy and the safety during treatment tocilizumab in patients completing treatment CWP-TCZ301 study with moderate to severe active RA and an inadequate response to current DMARD.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01256736?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
